Daniel has more than 15 years of experience in the biopharma industry, spanning roles in drug discovery, market analysis, competitive intelligence, and strategic consulting. Beginning his advisory career at Citeline, Daniel now oversees the thought leadership program for Norstella and its constituent companies, producing unique research that guides clients through ever-changing industry dynamics. As part of this, Daniel regularly participates in webinars, conferences, and other speaking arrangements, and he has provided expert insights across a wide range of leading industry and business publications. Prior to joining Citeline, Daniel worked as a medicinal chemist at Summit Therapeutics and graduated with First Class Honors in Natural Sciences from the University of Bath.
Latest from Daniel Chancellor
An extensive list of blockbuster drugs face patent expiry over the next six years, putting significant revenues at risk for major companies. While Eli Lilly and Novo Nordisk are reaping the rewards of GLP-1 successes, other large pharmas face steep challenges in closing their growth gaps.
As 2025 begins, the pharma industry is abuzz with discussions on pipeline strategies and China's growing role. With 30% of large pharma licensing deals now involving Chinese biotech, we take a whistlestop tour of the companies and regions driving this innovation.
A wealth of new therapies are set to successfully graduate from the pipeline in 2025. Within this cohort are a mixture of therapeutic areas, drug classes, first-time approvals, label expansions, and treatments that will meaningfully change how diseases are treated.
Profit warnings from CDMOs ring a warning bell that pharma is cutting its early research spend. What impact will spending controls and the tsunami of AI have on the pharmaceutical industry's R&D investments?
A recent analysis from Biomedtracker of clinical trial phase transitions between 2014 and 2023 suggests biopharma development success rates are falling. This poses several questions: what are the underlying reasons dragging success rates down and what does this mean for R&D productivity and the return on investment on pipeline spend?
France has long been a European leader in rare diseases, from its scientific research and academic hospitals, through to patient advocacy and regulatory reforms that have encouraged R&D. Its biotech and pharmaceutical industries are now leading the way, discovering the next generation of therapies for patients that are often overlooked.